Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation
Open Access
Abstract
Mutations in the NF1 gene cause Neurofibromatosis Type 1 (NF1), one of the most common genetic disorders. This gene encodes neurofibromin, a member of the GTPase-activating protein (GAP) family that functions as a negative regulator of RAS signaling. Loss of NF1 function leads to persistent RAS activation and promotes tumor growth. The clinical manifestations of NF1 mainly include pigmentary changes, benign and malignant peripheral nerve sheath tumors, as well as gliomas affecting the central nervous system. Currently, MEK inhibition is the only approved therapy and is primarily effective in controlling plexiform neurofibromas (pNFs). However, more comprehensive treatments are needed to address the full spectrum of NF1 manifestations and malignant transformation. Novel therapeutic strategies, including AAV-based gene therapy aimed at restoring NF1 function, oncolytic herpes simplex virus (oHSV) therapy targeting RAS-dysregulated tumor cells, and chimeric antigen receptor T cell (CAR-T) therapy targeting NF1-associated tumors, are under active investigation. In this review, we explore the genetic mechanisms underlying NF1 and highlight recent advances in therapeutic development with a special focus on AAV-based gene therapies alongside other approaches with recent clinical and translational advancements.Keywords
This publication has 134 references indexed in Scilit:
- Psychosocial functioning and determinants of the health-related quality of life in children with neurofibromatosis type 1 and cognitive impairmentsJournal of Neuro-Oncology, 2025
- Craniofacial bone alterations in patients with neurofibromatosis type 1Child's Nervous System, 2020
- Upregulated immuno-modulator PD-L1 in malignant peripheral nerve sheath tumors provides a potential biomarker and a therapeutic targetCancer Immunology, Immunotherapy, 2020
- Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohortPediatric Blood & Cancer, 2015
- Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor2014
- A novel neurofibromin (NF1) interaction with the leucine‐rich pentatricopeptide repeat motif‐containing protein links neurofibromatosis type 1 and the french canadian variant of leigh's syndrome in a common molecular complexJournal of Neuroscience Research, 2013
- Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromasPediatric Blood & Cancer, 2012
- Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)Investigational New Drugs, 2010
- Prevalence of Neurofibromatosis 1 in German Children at Elementary School EnrollmentArchives of Dermatology, 2005
- Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissuesDevelopmental Dynamics, 1995